Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 18,921 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $49.57, for a total value of $937,913.97. Following the transaction, the chief executive officer directly owned 467,187 shares of the company’s stock, valued at approximately $23,158,459.59. The trade was a 3.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Abraham Ceesay also recently made the following trade(s):
- On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58.
- On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The shares were sold at an average price of $46.26, for a total transaction of $1,042,746.66.
- On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10.
Rapport Therapeutics Price Performance
RAPP stock opened at $52.50 on Thursday. The company has a 50 day simple moving average of $42.90 and a 200 day simple moving average of $36.62. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -17.27 and a beta of 0.97. Rapport Therapeutics, Inc. has a 1 year low of $14.11 and a 1 year high of $52.83.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. HC Wainwright upped their target price on Rapport Therapeutics from $40.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Leerink Partners initiated coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 target price for the company. BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Rapport Therapeutics in a research report on Wednesday, August 19th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $75.00 price target on shares of Rapport Therapeutics in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $62.86.
Check Out Our Latest Report on Rapport Therapeutics
Hedge Funds Weigh In On Rapport Therapeutics
Large investors have recently modified their holdings of the business. TRV GP V LLC acquired a new position in shares of Rapport Therapeutics during the second quarter worth $261,709,477,000. ARCH Venture Management LLC acquired a new stake in Rapport Therapeutics in the second quarter valued at $155,376,512,000. Goldman Sachs Group Inc. increased its holdings in Rapport Therapeutics by 23.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after purchasing an additional 579,903 shares during the period. BlackRock Inc. bought a new position in Rapport Therapeutics during the 2nd quarter worth $112,500,000. Finally, Vanguard Group Inc. raised its position in Rapport Therapeutics by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after purchasing an additional 191,219 shares during the last quarter.
About Rapport Therapeutics
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
- Five stocks we like better than Rapport Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
